Physician profile
Robert C Yee
NPI 1104837764
$1,454.79
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $271.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $344.75 | 2019-2020 | |
| Amgen INC. | $228.76 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $156.44 | 2019-2020 | |
| Celgene Corporation | $127.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $116.13 | 2019 | |
| Astellas Pharma US INC | $92.85 | 2019-2020 | |
| Novo Nordisk INC | $67.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $61.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $55.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $38.22 | 2019-2020 | |
| Pfizer INC. | $31.50 | 2019-2020 | |
| Abbvie INC. | $30.01 | 2020 | |
| Eisai INC. | $21.07 | 2020 | |
| Assertio Therapeutics, INC. | $15.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $13.28 | 2019 | |
| Lilly USA, LLC | $12.79 | 2019 | |
| Allergan, INC. | $11.16 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.